LTR Pharma Limited (ASX:LTP)

Market Cap	97.22M
Revenue (ttm)	1.51M +2,978.2%
Net Income	-5.59M
EPS	-0.03
Shares Out	181.73M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	251,772
Average Volume	322,380
Open	0.5550
Previous Close	0.5500
Day's Range	0.5300 - 0.5550
52-Week Range	0.2700 - 0.8200
Beta	5.88
RSI	41.43
Earnings Date	Feb 26, 2026

About LTR Pharma

LTR Pharma Limited, a clinical-stage pharmaceutical company, engages in the research and development of intranasal spray for the treatment erectile dysfunction (ED) in Australia. Its lead product candidate is SPONTAN, an intranasal delivery technology, an oral PDE5 inhibitor and vardenafil HCL for the treatment of ED. The company was incorporated in 2020 and is headquartered in Brisbane, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: LTP

Financial Performance

In 2025, LTR Pharma's revenue was 1.51 million, an increase of 2978.25% compared to the previous year's 49,002. Losses were -5.59 million, -19.57% less than in 2024.